NASDAQ:MITI - Amgen Rockville Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Amgen Rockville Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileEarningsFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Designs and develops antibody-based drugs for treatment of cancer. The Company is a biotechnology company with a focus on the development of antibody-based products for cancer and inflammatory and autoimmune diseases. Micromet has established a drug development platform based on its BiTE technology, a drug format that leverages the cytotoxic potential of T cells. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:MITI Previous Symbol CUSIPN/A CIK1131907 Webhttp://www.micromet.com/ Phone+1-240-7521420Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive MITI News and Ratings via Email Sign-up to receive the latest news and ratings for MITI and its competitors with MarketBeat's FREE daily newsletter. Amgen Rockville (NASDAQ:MITI) Frequently Asked Questions What is Amgen Rockville's stock symbol? Amgen Rockville trades on the NASDAQ under the ticker symbol "MITI." Has Amgen Rockville been receiving favorable news coverage? News headlines about MITI stock have been trending negative recently, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amgen Rockville earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Amgen Rockville. What is Amgen Rockville's official website? The official website for Amgen Rockville is http://www.micromet.com/. How can I contact Amgen Rockville? Amgen Rockville's mailing address is 9201 Corporate Blvd Ste 400, ROCKVILLE, MD 20850-7209, United States. The biotechnology company can be reached via phone at +1-240-7521420. MarketBeat Community Rating for Amgen Rockville (NASDAQ MITI)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 99 (Vote Outperform)Underperform Votes: 75 (Vote Underperform)Total Votes: 174MarketBeat's community ratings are surveys of what our community members think about Amgen Rockville and other stocks. Vote "Outperform" if you believe MITI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MITI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/10/2019 by MarketBeat.com StaffFeatured Article: What is an Initial Public Offering (IPO)?